Monobody

特許 権利維持 Monobodies, also known as Adnectins, are genetically engineered proteins that are able to bind to antigens. Despite their name, they are not parts of antibodies, which makes them a type of antibody mimetic. They are being developed by Adnexus, a biotechnology company which has been part of Bristol-Myers Squibb since 2007. An example is pegdinetanib (Angiocept), an antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2), which has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007.